Ligand Pharmaceuticals, Inc.

Ian Henderson

Jinkun Zhang

Zofia E Dziewanowska

Rene Belder

Joseph B Bogardus

Zhaoying Zhang

Lin Zhi

Martin Osterhout

Joseph Kaloko

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

Glucagon receptor antagonists

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Method for treating disorders associated with glomerular function

Method for treating glomerulosclerosis

Growing community of inventors

San Diego, CA, United States of America

Ian Henderson